Patents by Inventor Kasumi NINOMIYA

Kasumi NINOMIYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment method for epithelial cancerous organism
    Patent number: 8637084
    Abstract: It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising: step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; and step (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: January 28, 2014
    Assignees: Asahi Kasei Medical Co., Ltd., National Cancer Center
    Inventors: Mikitomo Yasutake, Kasumi Ninomiya, Junichi Honda, Atsushi Ochiai, Chisako Yamauchi
  • TREATMENT METHOD FOR EPITHELIAL CANCEROUS ORGANISM
    Publication number: 20110091471
    Abstract: It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising: step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; and step (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.
    Type: Application
    Filed: July 13, 2010
    Publication date: April 21, 2011
    Applicants: ASAHI KASEI KURARAY MEDICAL CO., LTD., NATIONAL CANCER CENTER
    Inventors: Mikitomo YASUTAKE, Kasumi NINOMIYA, Junichi HONDA, Atsushi OCHIAI, Chisako YAMAUCHI